{"id":"W2598147971","doi":"10.1200/jco.2017.35.4_suppl.tps503","title":"KEYNOTE-240: Randomized phase III study of pembrolizumab versus best supportive care for second-line advanced hepatocellular carcinoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Pembrolizumab; Hepatocellular carcinoma; Internal medicine; Adverse effect; Placebo; Milan criteria; Liver disease; Transplantation; Response Evaluation Criteria in Solid Tumors; Liver transplantation; Oncology; Surgery; Phases of clinical research; Clinical trial; Cancer; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002501215,0.002318487,0.002423951,0.0005911272,0.0004616679,0.001367503,0.001329101,0.002009158,0.01962313],"category_scores_gemma":[0.001650511,0.0009178463,0.001832374,0.0004620618,0.001255987,0.001384128,0.0005159907,0.003967583,0.003093858],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001024208,"about_ca_system_score_gemma":0.002046628,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001007837,"about_ca_topic_score_gemma":0.002602748,"domain_scores_codex":[0.9994173,0.0002840479,0.00002897849,0.0001004181,0.00005567838,0.000113714],"domain_scores_gemma":[0.9992137,0.0001525321,0.0001794395,0.00005973181,0.00005207357,0.0003425387],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.974207,0.007945741,0.000261359,0.0005732462,0.000535696,0.00003729959,0.00002859291,0.000260418,0.002467217,0.0001677143,0.002284488,0.01123124],"study_design_scores_gemma":[0.9634402,0.03489641,0.0004258078,0.00001905481,0.0001309399,0.00001903605,0.000008315639,0.0001751946,0.0001652259,0.00009121797,0.0006217904,0.00000672466],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9294257,0.008098735,0.002105766,0.002978181,0.002843302,0.03133204,0.0107443,0.0008440371,0.01162802],"genre_scores_gemma":[0.9375018,0.004630589,0.003268848,0.004672002,0.0009605566,0.02816734,0.006698489,0.0001024031,0.01399794],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01962313,"threshold_uncertainty_score":0.06564593,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2289387289289545,"score_gpt":0.4701466967084291,"score_spread":0.2412079677794746,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}